Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

Tweets about clinical trials link to relevant resources where patients, their carers or doctors can find more information; many link to US clinical trials site clinicaltrials.gov, or Novartis ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

The FDA on Thursday approved Fabhalta (iptacopan) to treat complement 3 glomerulopathy (CG3), a progressive, ultrarare kidney ...

Entresto, approved in heart failure since 2015, has long been one of Novartis’ top growth drivers, bringing home $4.05 billion in U.S. sales in 2024. That said, a key combination patent on the ...

Novartis is the ideal partner to help us in this mission due ... We are proud to build on our legacy to deliver science-backed guidance, innovative resources, and steadfast support for patients, ...

Novartis said that the latest round of job losses is a result of a change in focus for its cardiovascular teams as they lower the emphasis on Entresto and devote more resources to its twice-yearly ...

Novartis is paying Kyorin $55 million upfront for exclusive global rights to develop, manufacture and commercialize KRP-M223, a preclinical mast-cell-targeting candidate for chronic spontaneous ...

Novartis AG (NYSE:NVS – Get Free Report) was the target of some unusual options trading activity on Tuesday. Investors acquired 54,767 call options on the stock. This represents an increase of 2,389% ...